Recommendation

Want to access this article for free?

In our update on ResMed’s recent third-quarter result we warned that there would be some fireworks in ResMed’s share price when the results of its SERVE-HF clinical trial were to be announced later this year. Well they’ve been reported early and the news is not good.

The trial was conducted on patients suffering from central sleep apnea (CSA) as well as symptomatic chronic heart failure. CSA, often seen in heart failure patients, is where the brain and nervous system fail to provide the right...

Dear II team I see on ASX update page that the recent dividend is quoted at 15.596c and you have it as 3.05c. I pull the ASX div data into my spreadsheet and got all excited with a huge div from RMD but quickly realised it must be an error on ASX'...

InvestSMART Publishing Pty Ltd holds Australian Financial Securities Licence (AFSL) 282288.
The content of this website is general in nature and does not take the personal situation of any user of this website into consideration.
A user of this website should seek financial advice specific to that user’s situation before making any financial decision.
Past performance of any security or financial product is not a reliable indicator of future performance. InvestSMART Publishing Pty Ltd
encourages users of this website to view investing as a long-term pursuit.